Actuate Therapeutics Initiates Elraglusib Clinical Trial
Actuate Therapeutics announced plans to initiate a Phase 1/2 clinical program evaluating the oral tablet dosage form of elraglusib in patients with advanced cancer. The phase 1 portion of the planned Phase 1/2 program aims to determine the maximum tolerated dose or maximum administered dose and dose-limiting toxicities of elraglusib tablets administered once daily and will investigate the pharmacokinetics of elraglusib tablets as well as the preliminary anti-tumor activity of elraglusib when administered as tablets. The goal of the phase 1 portion of the program will be to establish the recommended dose of elraglusib tablets for expansion in subsequent development
